NCT06931626
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: The decision about study closure has not been based on safety profile or clinical data of NMS-03305293 but due to a strategic decision driven by upcoming changes in the treatment landscape. Show 6 more changesShow less
- Eligibility criteria expanded, about 26 words
- Final enrollment: 5 participants (planned 10)
- Primary completion date changed from estimate of Oct 30, 2026 to Aug 20, 2026
- Study completion date changed from estimate of Feb 28, 2027 to Sep 21, 2026
- Secondary endpoints: details revised at 4 of 16 entries
- Site details revised at 3 of 3 sites
- Notable Eligibility criteria expanded, about 47 words
- Study sites: 2 to 3
- Minor Study sites: 1 to 2v5
- Minor Start date changed from estimate of Sep 15, 2025 to Aug 15, 2025v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Aug 1, 2025 to Sep 15, 2025
- Eligibility criteria expanded, about 17 words
- Study sites: 0 to 1
- Notable Start date: Jun 30, 2025 to Aug 1, 2025
- Primary completion date: Nov 27, 2026 to Oct 30, 2026
- Study completion date: Nov 27, 2026 to Feb 28, 2027
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants with Adverse Events (AEs)
Timeframe: Screening (Day ≤28) up to 28-day follow-up after end of treatment (Approximately 12 months)
Secondary (16)
Overall Response Rate (ORR)
Duration of response (DoR)
Progression-free survival (PFS)
Overall survival (OS)
Maximum plasma concentration (Cmax) of NMS-03305293
Show 11 moreShow less
Time to maximum plasma concentration (Tmax) of NMS-03305293
Area under the plasma concentration versus time curve up to the last detectable concentration (AUC) for NMS-03305293
Minimum plasma concentration (Cmin) of NMS-03305293
Average plasma concentration (Cave) of NMS-03305293
Area under the plasma concentration versus time curve to infinity (AUCinf) for NMS-03305293
Terminal elimination half-life (t1/2) of NMS-03305293
Oral plasma clearance (CL/F) of NMS-03305293
Apparent volume of distribution (Vd/F) of NMS-03305293
Accumulation ratio (Rac) of Cmax for NMS-03305293
Rac of Area under the plasma concentration vs time curve within dosing interval (AUCdaily) for NMS-03305293
Rac of Area under the plasma concentration up to the last detectable plasma concentration (AUClast) for NMS-03305293
Arms and interventions
NMS-03305293 and TemozolomideExperimental
NMS-03305293 will be dosed orally on days 1-28 of each 28-day cycle, at 100 mg twice daily. Temozolomide will be dosed orally on days 1-5 of each 28-day cycle, at 150 mg/m\^2, based on patients' body surface area.
Drugs: NMS-03305293, Temozolomide
Sites
3 sites in 1 country